<DOC>
	<DOCNO>NCT02472236</DOCNO>
	<brief_summary>To assess effect PEX168 dose pharmacokinetics digoxin healthy subjects.To provide scientific basis clinical drug combination PEX168 . To assess safety single dose digoxin administer without PEX168</brief_summary>
	<brief_title>Evaluate Pharmacokinetics Digoxin When Coadministered With PEX168 Healthy Adult Subjects</brief_title>
	<detailed_description>This open-label , sequential , single-center study evaluate pharmacokinetics digoxin coadministered PEX168 healthy adult subject . The total duration subject 's participation study approximately 12 week , include 14-day Screening Period , 44-day Treatment Period , approximately 4-week Follow-up Period . Center : This study conduct single site first affiliate hospital Xi'an Jiaotong University.All subject receive single 0.5mg oral dose digoxin Day 1 follow 5 weekly 200μg dos PEX168 inject subcutaneously begin Day 8 second single 0.5mg oral dose digoxin Day 38 .</detailed_description>
	<mesh_term>Digoxin</mesh_term>
	<criteria>1 . Healthy male age 18 45 year ( include end ) time sign informed consent . 2 . Weighing less 50kg，Body Mass Index ( BMI ) 18 25kg/m2 . 3 . Alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , alkaline phosphatase ( ALP ) , total bilirubin ( Tbil ) within normal range screening ; 4 . Estimated creatinine clearance ( Clcr ) ≥90ml / min calculate CockcroftGault ( CG ) formula ; 5 . Capable give write informed consent , include compliance requirement restriction list consent form . 1 . The hepatitis B surface antigen , hepatitis C antibody , HIV antibody test positive ; 2 . Having history syncope , palpitation , bradycardia , tachycardia anomaly ( extent way block , leave bundle branch block , right bundle branch block ) , via comprehensive physical examination ( vital sign , physical examination ) , routine laboratory test ( blood count , blood biochemistry , urine , etc . ) , 12lead ECG , abdominal B ultrasound ( liver , gallbladder , pancreas , spleen , kidney ) , abnormalities clinical significance person screen ; 3 . Having Alcohol drug abuse within first 6 month screen ; 4 . Smoked within 3 month screen ; 5 . In screen period , blood pressure great 140 / 90mmHg , retest diagnosis pulse rate high 100bpm person ; 6 . In screen period , ECG QTc &gt; 450ms , diagnose retest ; 7 . Having history drug allergic reaction allergic constitution hypersensitivity follow : 1 ) digoxin / ingredient similar drug . 2 ) PEX168 8 . Before screen , history cardiovascular disease ( coronary heart disease , high blood pressure , high cholesterol , etc . ) history pulmonary disease ( chronic bronchitis , emphysema , asthma , pneumonia , etc . ) ; 9 . In screen period , fast triglyceride test result great upper limit normal range ; 10 . Currently history liver disease liver disease know hepatobiliary abnormality ( except asymptomatic gallstone ) ; 11 . Participate blood donation donation amount ≥400ml within three month screen , participate blood donation blood transfusion within month ; 12 . In screen period , thyroid dysfunction history ; 13 . The history gastrointestinal surgery ( stomach cut surgery , gastric bypass surgery ) screening ; 14 . The history pancreatitis ; 15 . History cholecystitis gallbladder disease disease history ; 16 . The history inflammatory bowel disease history irritable bowel syndrome ; 17 . The history Type 2 multiple endocrine neoplasia ; 18 . The history medullary thyroid cancer ; 19 . The family type 2 multiple endocrine fibromatosis history medullary thyroid cancer ; 20 . 3 month screen , participate drug medical device trial ( include placebo ) ; 21 . Using tested drug may affect prescription drug , nonprescription drug , herbal ( especially ginseng , oral hypoglycemic agent ) multivitamin supplement person ; 22 . Drinking medication caffeinecontaining xanthine food beverage ( list annex 3 ) , strenuous exercise , effect drug absorption , distribution , metabolism , excretion factor 2 day screen . 23 . Received GLP1 analog ( e.g . exenatide ) treatment ; 24 . Reluctant take effective method contraception test , fertility planner within six month spouse test last dose ( 38 day ) ; 25 . Researchers believe situation might lead subject complete study subject study bring significant risk .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
</DOC>